Business
Karyopharm Announces XPOVIO® (Selinexor) Clinical Data to be Presented at the American Society of Hematology 2020 Annual Meeting
-- Updated Results from the Pomalyst®, Kyprolis® and Revlimid® Arms of the Phase 1b/2 STOMP Study Evaluating XPOVIO in Combination with Other Approved Myeloma
About this update from Karyopharm Therapeutics Inc.
[{"type":"text","content":"-- Updated Results from the Pomalyst®, Kyprolis® and Revlimid® Arms of the Phase 1b/2 STOMP Study Evaluating XPOVIO in Combination with Other Approved Myeloma Therapies in Relapsed or Refractory Multiple Myeloma to be Presented --\n -- Other Key Presentations Include Multiple New Subanalyses from the Pivotal Phase 3 BOSTON Study in Multiple Myeloma Following at Least One Prior Line of Therapy and from the Phase 2b SADAL Study in Relapsed or Refractory DLBCL --\n -- Company to Host Virtual Investor and Analyst Event in December 2020 to Review Highlights from the Data Presented at ASH 2020--\n\n\n NEWTON, Mass., Nov. 4, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that twenty-one abstracts have been selected for virtual presentation, including two oral presentations, at the upcoming American Society of Hematology (ASH) 2020 Annual Meeting taking place December 5-8, 2020. Key abstracts to be presented at the meeting will feature clinical data for XPOVIO® (selinexor), the Company's first in class, oral SINE compound, including: (i) updated data from the Pomalyst® (pomalidomide), Kyprolis® (carfilzomib) and Revlimid® (lenalidomide) arms of the Phase 1b/2 STOMP study evaluating XPOVIO in combination with backbone therapies in patients with relapsed or refractory multiple myeloma; (ii) several new subgroup analyses from the pivotal Phase 3 BOSTON study evaluating once weekly XPOVIO in combination with once weekly Velcade® (bortezomib) and low-dose dexamethasone against standard twice weekly Velcade in adult patients with multiple myeloma who had received one to three prior lines of therapy; and (iii) new subgroup analyses from the Phase 2b SADAL study evaluating XPOVIO in relapsed or refractory diffuse large B-cell lymphoma (DLBCL).\n\"Our tradition of having a strong presence at the ASH annual meeting continues this year and we are excited to share important clinical data from a variety of our XPOVIO clinical studies,\" said Sharon Shacham, PhD, MBA, Founder, President and Chief Scientific Officer of Karyopharm. \"In total, twenty-one abstracts have been selected, including an oral presentation highlighting the all-oral regimen of XPOVIO and Pomalyst® from the ongoing STOMP study. Additionally, updated data from two other ...